Arrowhead Pharmaceuticals, Inc. (0HI3.L) LSE

Currency In USD

AD

Valuation

Market Cap4.53B
Enterprise Value5.04B
P/E Ratio-36.95
PEG Ratio0
Price/Sales Ratio17.41
Price/Book Ratio25.49
Enterprise/Revenue18.62
Enterprise/EBITDA-88.84

Fiscal Year

Fiscal YearSeptember 30, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.48
Operating Margin-0.34
AD

Management Effectiveness

Return On Assets-0.15
Return On Equity-0.61

Income Statement

Revenue829.45M
Revenue/Share4.67
Gross Profit805.52M
EBITDA164.82M
Net Income-1.63M
Diluted EPS-0.01

Balance Sheet

Total Cash1.6B
Total Cash/Share11.17
Total Debt1.38B
Total Debt/Equity1.86
Current Ratio5.9
Book Value Per Share3.25

Price History

52-Week Change185.02
52-Week High83.36
52-Week Low20.75
Moving Average 50 Days32.83
Moving Average 200 Days31.06

Statistics

Average Volume1,779
Shares Outstanding139.12M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio-0.12
Last Split FactorN/A
Last Split DateN/A
AD